Pharma&, Rubraca Approved in Europe for First-Line Maintenance Treatment of Ovarian Cancer
European Approval Overcomes Biomarker Barriers
The European Commission approved Rubraca (rucaparib) from Pharma& for first-line maintenance treatment of ovarian cancer in November 2023. This approval is for patients with FIGO stage 3 or 4, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have undergone first-line platinum-based chemotherapy with complete or partial response. It can be used regardless of BRCA mutation or homologous recombination deficiency (HRD) status, expanding the treatable population. The treatment duration is until progression or intolerance, with a maximum of 2 years.
Reduced Risk of Disease Progression by Approximately Half in Phase 3
The approval is based on the Phase 3 ATHENA-MONO study (NCT03522246), which randomized 538 newly diagnosed patients to receive rucaparib or placebo. The median progression-free survival (mPFS) in the overall study population was 20.2 months versus 9.2 months, with a hazard ratio (HR) of 0.52, a 95% confidence interval of 0.40 to 0.68, and a p-value of less than 0.0001. In the HRD-positive group, it was 28.7 months versus 11.3 months, with an HR of 0.47, and in the HRD-negative group, it was 12.1 months versus 9.1 months, with an HR of 0.65, providing evidence for a broad label.
Competitive Landscape Depends More on Reimbursement than Efficacy
The main competitors are Lynparza (olaparib, a PARP1/2 inhibitor) from AstraZeneca and Merck, and Zejula (niraparib, a PARP1/2 inhibitor) from GSK, as well as Lynparza in combination with Avastin (bevacizumab, a VEGF-A inhibitor) in HRD-positive patients. Lynparza recorded global product sales of $2.811 billion in 2023, establishing a leading position in the PARP inhibitor market in terms of prescription and reimbursement. Rubraca's all-patient data is a differentiating factor, but actual market share will depend on country-specific pricing, reimbursement, and physician experience.
Acquisition of Bankrupt Assets Transformed into Regulatory Value
Clovis Oncology filed for Chapter 11 bankruptcy in December 2022, and Pharma& acquired the Rubraca business in 2023 for a $70 million upfront payment. The agreement includes regulatory milestone payments of up to $50 million and sales milestone payments of up to $15 million. This European approval for first-line maintenance treatment triggers a $10 million payment. Rubraca received conditional approval in the EU in May 2018 and transitioned to standard approval in November 2022. Following a positive CHMP opinion in 2023, the indication was expanded, extending the commercial life of the acquired asset as a first-line treatment.
In the Phase 3 ATHENA-MONO trial, the overall patient population had an mPFS of 20.2 months, compared to 9.2 months for the placebo group, with an HR of 0.52. This demonstrates that Rubraca has a competitive advantage as an approved first-line maintenance treatment, including for patients with HRD-negative status. In the short term, Pharma& will be responsible for the $10 million regulatory milestone payment linked to the European approval and will need to expand its revenue base through reimbursement listings in each country. In the medium to long term, the main competitors are Lynparza, with product sales of $2.811 billion in 2023, and GSK's Zejula. To change the established prescription practices, clinical efficacy, pricing, and supply capabilities will be necessary. For researchers, the HR of 0.65 in the HRD-negative group provides evidence for biomarker-independent PARP maintenance therapy, but tracking of overall survival and long-term safety, including myelodysplastic syndrome and acute myeloid leukemia, is important for determining the sequence of treatment.
Source: EMA (ema)